Skip to content

Simulations Plus, Inc. (SLP) — Institutional Holders & Catalysts | BiotechEdge

BiotechEdgeNew: AI Alerts

Catalysts Convergence Squeeze Signals Cash Runway Insiders Research

Sign In Start 14-Day Free Trial

Home›Companies›Simulations Plus, Inc. (SLP)

Simulations Plus, Inc.

SLP

Held by 1 specialist biotech fund

1 fund opened new positions. Short interest: 8.8% of float.

Share

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

2.2/10

1 fund opened new positions

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

●●

No recent insider activity●●

No upcoming catalysts●●

Held by 1 specialist fund●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

Deerfield Management

Position history (shares)

Deerfield Management

2Q

AI Signal

SIGNAL NOTE: Deerfield Exit from SLP

Deerfield's exit from Simulations Plus—a computational modeling platform for drug development—suggests loss of conviction in the company's commercial trajectory or platform monetization. SLP lacks a proprietary late-stage pipeline; its value proposition depends entirely on pharma/biotech adoption of its software, making it vulnerable to end-market weakness and customer concentration risk.

Unlock full AI analysis — 14-day free trial

2 quarters

Position Trend

May 15, 2025

$8.7M

1 fund

Aug 14, 2025

$6.2M

1 fund

Nov 14, 2025

$0

0 funds

Feb 17, 2026

$0

0 funds

-100% total institutional value over 4 quarters

Short Interest

Short Shares

1.25M

Change

-3.1%

Days to Cover

4.9

% of Float

8.8%

Settlement

Mar 13, 2026

Short interest over 2 periods

Catalysts

No catalysts tracked.

Position Details

Deerfield ManagementEXITFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

3 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

CPRX1 fund RXST1 fund GPCR1 fund SGRY1 fund TNGX1 fund TRUP1 fund VERA1 fund RDNT1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: